{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:49:54Z","timestamp":1765486194251,"version":"3.41.2"},"reference-count":8,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI121430"],"award-info":[{"award-number":["R01 AI121430"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Fosfomycin is the only expoxide antimicrobial and is currently under development in the United States as an intravenously administered product. We were interested in identifying the exposure indices most closely linked to its ability to kill bacterial cells and to suppress amplification of less susceptible subpopulations. We employed the hollow fiber infection model for this investigation and studied wild-type strain\n            <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n            PAO1. Because of anticipated rapid resistance emergence, we shortened the study duration to 24 h but sampled the system more intensively. Doses of 12 and 18 g\/day and schedules of daily administration, administration every 8 h, and administration by continuous infusion for each daily dose were studied. We measured fosfomycin concentrations (by liquid chromatography-tandem mass spectrometry), the total bacterial burden, and the burden of less susceptible isolates. We applied a mathematical model to all the data simultaneously. There was a rapid emergence of resistance with all doses and schedules. Prior to resistance emergence, an initial kill of 2 to 3 log\n            <jats:sub>10<\/jats:sub>\n            (CFU\/ml) was observed. The model demonstrated that the area under the concentration-time curve\/MIC ratio was linked to total bacterial kill, while the time that the concentration remained above the MIC (or, equivalently, the minimum concentration\/MIC ratio) was linked to resistance suppression. These findings were also seen in other investigations with\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            (\n            <jats:italic>in vitro<\/jats:italic>\n            systems) and\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            (murine system). We conclude that for serious infections with high bacterial burdens, fosfomycin may be of value as a new therapeutic and may be optimized by administering the agent as a continuous or prolonged infusion or by use of a short dosing interval. For indications such as ventilator-associated bacterial pneumonia, it may be prudent to administer fosfomycin as part of a combination regimen.\n          <\/jats:p>","DOI":"10.1128\/aac.02627-17","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T10:03:04Z","timestamp":1521712984000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":22,"title":["Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model"],"prefix":"10.1128","volume":"62","author":[{"given":"Arnold","family":"Louie","sequence":"first","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida, Lake Nona, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Maynard","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida, Lake Nona, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Duncanson","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida, Lake Nona, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyn","family":"Nole","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida, Lake Nona, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Vicchiarelli","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida, Lake Nona, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. L.","family":"Drusano","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida, Lake Nona, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02177-15"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02231-15"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.166.3901.122"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00752-15"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04955-14"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00476-17"},{"key":"e_1_3_2_8_2","volume-title":"CLSI document M07-A9","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_9_2","first-page":"389","volume-title":"In Proceedings of the 14th IEEE Symposium on Computer-Based Medical Systems","author":"Leary RH","year":"2001","unstructured":"Leary RH, Jelliffe R, Schumitzky A, Van Guilder M. 2001. An adaptive grid non-parametric approach to population pharmacokinetic\/dynamic (PK\/PD) population models, p 389\u2013394. In Proceedings of the 14th IEEE Symposium on Computer-Based Medical Systems. IEEE, New York, NY."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02627-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02627-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:16:36Z","timestamp":1645478196000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02627-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1128\/AAC.02627-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.02627-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"2017-12-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02627-17"}}